-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pernisson is a common drug for the treatment of severe muscle weakness (MG), but after the patient's condition is under control, its reduction plan has not been fully validated.
researchers recently compared the effects of the Pernisson slow-down program vs the fast-reducing program on patients' condition.
In this study, a multi-center, parallel, single-blind randomized trial compared the effectiveness of two pernisone reduction regimens with the participation of adult patients with moderate to severe MG, where the standard slow-reducing options were as follows: the dose of pernisone therapy was first slowly increased to 1.5 mg/kg every 1 day. Take 1 time, then slowly reduce to maintain the dose to keep MG symptoms to a minimum, the rapid reduction program is as follows: the patient can be given 0.75 mg/kg of pernisone treatment dose, 1 time a day, the patient MG symptoms control, then began to rapidly reduce the amount, and always maintain MG symptoms at the lowest level.
all participants were treated with methotrexate thiopental at a maximum dose of 3 mg/kg/d.
of the study was 12 months without pernisone treatment and the patient's condition remained at the lowest level of MG symptoms and there was no recurrence at 15 months.
117 patients were involved in the study, including 58 in the slow-down group, 59 in the fast-reducing group and 62 in men, with an average age of 65.
group of 23 reached the main finish line, while the slow-down group had only 5 people (39% vs. 9%), with an advantage ratio of 3.61.
, the average dose of per patient in the rapid reduction group was 5.3 mg/d per year.
rates of serious adverse events between groups (22% vs. 36%). the
study found that for patients with moderate to severe muscle weakness who needed to be treated with high doses of pernisone, it was feasible to use shock therapy with an initial dose of 0.75 mg/kg and then enter a rapid reduction programme to maintain the lowest level of the disease, which was well-to-resistant and had better clinical control than the current programme.
